Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

According to the report, Huntingtin (Huntington Disease Protein or HTT) pipeline Target constitutes close to 16 molecules, out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

The report outlays comprehensive information on the Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type that are being developed by Companies/Universities.

It also reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, the molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 6 and 5 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. The report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Huntington Disease, Alzheimer’s Disease, Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) and Spinocerebellar Ataxia (SCA).

Featured News & Press Releases

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease Voyager Therapeutics Announces New Data on VY-HTT01 at the American Society of Gene and Cell Therapy 2018 Annual Meeting uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington’s Disease Genentech to Present Phase I/IIa Data of RG6042 at AAN Patent Issues for Novel Huntington and Alzheimer’s Disease Gene Therapy

Companies Featured

AFFiRiS AG Exicure Inc. F. Hoffmann-La Roche Ltd. Neurimmune Holding AG nLife Therapeutics SL PTC Therapeutics Inc. reMYND NV Shire PLC UniQure NV Voyager Therapeutics Inc. Vybion Inc. WAVE Life Sciences Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vtmrhs/huntingtin?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005582/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 01:00 PM/DISC: 09/17/2018 01:01 PM


Update hourly